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Background: Diabetes mellitus (DM) has been associated with the cancer risk. This study investigated relationship
between DM and esophageal cancer using Taiwan’s insurance data.
Methods: We identified 549 patients with esophageal cancer newly diagnosed in 2000-2009 and randomly
selected 2196 controls without any cancer, frequency matched by sex, age and diagnosis year of cases. Logistic
regression model estimated odds ratios (ORs) and 95% confidence intervals (CI) of esophageal cancer associated
with DM, sex, age. co-morbidities and medications.
Results: Cases were more prevalent than controls for alcoholism and esophageal disorders and using nonsteroidal
anti-inflammatory drugs (NSAIDs) and cyclooxygenase-2 inhibitors but not DM. Esophageal cancer had no
association with DM (OR 0.99, 95% CI 0.71-1.37), but significantly associated with alcoholism (OR 14.1, 95% CI 7.87-
25.4), esophageal ulcer (OR 10.1, 95% CI 5.70-17.9), esophageal reflux (OR 3.47, 95% CI 2.14-5.26) and uses of NSAIDs
(OR 2.73, 95% CI 1.80-4.13). An elevated risk of esophageal cancer appeared in DM patients taking insulin (OR 2.57,
95% CI 1.08-6.15) or sulfonyurea (OR 3.80, 95% CI 1.16-12.5).
Conclusions: Patients with DM are not at higher risk for esophagus cancer. However, esophageal disorders and
anti-diabetic drugs are associated with the risk of the disease.
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Glucose metabolism disorders (GMDs) such as diabetes
mellitus (DM), impaired fasting glucose regulation (IFG),
impaired glucose intolerance (IGT), and hypoglycemia
are systemic diseases that have been associated with
many other diseases including malignancy [1]. The esti-
mated prevalence of diabetes for all ages worldwide may
increase from 2.8% in 2000 to 4.4% in 2030 [2]. DM is
also a prevalent public health problem in Taiwan.
According to statistics, the mortality rates from DM
have almost doubled over the past 10 years in Taiwan.
The prevalence of DM in Taiwan has been higher than
5% since 1985 [3]. Studies have associated DM with
increased risk of cancers, such as esophageal cancer,
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reproduction in any medium, provided the orbreast cancer, and endometrial cancer [4-11]. The risk of
esophageal cancer linking with DM has been contro-
versy. A meta-analysis, including 6 case-control studies
and 11 cohort studies, found a summary relative risk of
2.72 (95% confidence interval (CI) 1.01-4.46) for esopha-
geal cancer linking with DM [8].
Esophagus cancer incidence has been rising rapidly in
many countries [12-16]. The incidence of esophageal
adenocarcinoma rose approximately sixfold in the
United States from 1975 to 2001 [15]. The 5-year mor-
tality rates may exceed 80% for patients with the cancer
[17]. Histological data have shown that populations with
esophageal cancer in the Western countries suffer
mainly from the adenocarcinoma [12-17]. Population in
Taiwan has exactly the other type of esophageal cancer;
approximately 95% patients have the squamous cell car-
cinoma [18]. The association between squamous cell car-
cinoma and DM in the Taiwan population may be
different from that between adenocarcinoma and DM in
the Western populations. This study was designed to useLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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evaluate whether the squamous cell carcinoma of the
esophagus is associated with DM.Methods
Data sources
This case-control study used data available from the Na-
tional Health Insurance (NHI) program in Taiwan. The
insurance program was integrated from all public insur-
ance programs in 1995 as a single payment program
[19-22]. The National Health Research Institutes are re-
sponsible to management the claims data and converted
the data into various data sets for research. This study
used the claims data of inpatient and out-patients of 1-
million insured people randomly selected from all 23-
million population. Data files can be linked with
scrambled identification to protect individual privacy.
Information on anthropometry, laboratory tests and life-
style was not available.Study subjects
This study identified 549 patients aged 20 years and
above newly diagnosed with esophageal cancer (ICD-9
150.X and V10.03) during the period of 2000-2009. The
index date for each case was the date of diagnosis of
esophageal cancer. For each esophageal cancer case, four
controls were randomly selected from the same data set
frequency matched by sex, age, and then the year the
case being selected when controls having a health care
visit in the same year. Subjects with esophageal cancer
and any other cancer (ICD-9 140-208 and A-code A08x-
A14x) identified by the index year were excluded. We
retrospectively screened to 1997 for the medical diagno-
sis of DM (ICD-9 250.xx and A-code A181) with pre-
scription of DM medication for each selected subject.
Similar process was performed to screen for co-
morbidities that may associate with the development of
esophageal cancer. They were alcoholism (ICD-9 codes
303, 305.00, 305.01, 305.02, 305.03, and V11.3 and A-
code A215), tobacco use disorders (ICD-9 codes
305.1X), periodontal disease (523.8 and 523.9X), HPV
infection (079.4), hyperlipidemia (272.0, 272.1, 272.2,
272.3 and 272.4), Barrett's esophagus (530.85), esopha-
geal ulcer (530.2), esophageal reflux (530.81, 530.11) and
esophageal burn (947.2). Other factors examined were
the use of nonsteroidal anti-inflammatory drugs
(NSAIDs) like aspirin, cyclooxygenase-2 inhibitors
(COX-2 inhibitors) and anti-diabetic drugs identified
from the prescription files. The anti-diabetic drugs
included metformin, sulfonylureas, thiazolidinediones,
alpha-glucosidase inhibitors, D-phenylalanine deriva-
tives, dipeptidyl peptidase 4 inhibitors, incretin mimetic
agents and insulins.Statistical analysis
We compared the distributions in sex, age, co-
morbidities and medications between esophageal cancer
cases and controls and tested differences using the Chi-
square test. The significant variables were further
included in the multivariate logistic regression analysis
to measure odds ratio (OR) and 95% CI for esophageal
cancer, with diabetes status forced in the analysis. Fur-
ther analyses explored whether the risk of esophageal
cancer was associated with the duration of diabetes (< 2
vs. ≥ 2 years) and using anti-diabetic drugs. The associ-
ation with anti-diabetic drug was estimated individually.
The statistical significance level was set at probability
value of < 0.05 (SAS software version 9.1, SAS Institute
Inc., Cary, North Carolina, USA).Ethical considerations
This study used surrogate identification for each study
subject to link study files to secure patient privacy. The
present study was exempted from a full ethical review.Results
Baseline characteristics
Table 1 compares the demographic characteristics and
co-morbidities between esophageal cancer cases and
controls. Both groups were predominantly men (92.9%)
with the mean age of 60.9 (standard deviations 3.03 vs.
12.9) years. There were no significant differences be-
tween cases and controls in the prevalence of DM
(10.4% vs. 10.1%, p = 0.85) and hyperlipidemia. Cases
were more prevalent with co-morbidities of alcoholism,
esophageal ulcer, esophageal reflux, and COX-2 inhibi-
tors except use of other NSAIDs.Risk measures
Table 2 shows that esophageal cancer was not related
to DM in both univariate and multivariate logistic
regression analyses (OR 0.99, 95% CI 0.71-1.37). Among
co-morbidities, esophageal cancer had the strongest
association with alcoholism (OR 14.1, 95% CI 7.87-25.4),
followed by esophagus ulcer (OR 10.1, 95% 5.70-17.9),
esophagus reflux (OR 3.47, 95% CI 2.14-5.62) and use of
other NSAIDs (OR 2.73, 95% CI 1.80-4.13). Table 2 also
shows a protective association between periodontal dis-
ease and esophageal cancer (OR 0.20, 95% CI 0.02-0.88).
Table 3 shows patients with DM for longer than 2 years
were at higher risk of the cancer than patients with
shorter DM history with an OR of 2.28 (95% CI 0.85-
6.08) after controlling for sex, age, alcoholism, periodon-
tal disease, esophagus ulcer, esophagus reflux, COX-2
inhibitors and other NSAIDs.
Table 1 Comparisons in socio-demographic status, co-
morbidity and medication between esophageal cancer





n % n % P value†
Age, mean (SD), years 60.9 (3.03) 60.9 (12.9) 0.24
20-39 56 2.55 14 2.55 1.00
40-64 1,328 60.5 332 60.5
≥65 812 37.0 203 37.0
Sex 1.00
Women 156 7.10 39 7.10
Men 2,040 92.9 510 92.9
Comorbidity
Diabetes mellitus 222 10.1 57 10.4 0.85
Alcoholism 16 0.73 53 9.65 <0.0001
Obesity 4 0.18 1 0.18 1.00†
Tobacco use disorder 7 0.32 5 0.91 0.07†
Periodontal disease 33 1.50 2 0.36 0.03†
HPV infection – – – – –
Hyperlipidemia 324 14.8 65 11.8 0.08
Barrett's esophagus – – – – –
Esophageal ulcer 18 0.82 50 9.11 <0.0001
Esophageal reflux 39 1.78 43 7.83 <0.0001
Medication
Use of aspirin 305 13.9 83 15.1 0.46
Use of COX-2 inhibitors 495 22.5 159 29.0 0.002
Use of other NSAIDs 1,877 85.5 522 95.1 <0.0001
Data are presented as the number of subjects in each group, with percentages
given in parentheses.
Chi-square test and †Fisher’s exact test comparing patients with and without
esophageal cancer.
Table 2 Crude and adjusted odds ratios and 95%
confidence intervals of esophageal cancer associated
with diabetes and covariates
Crude Adjusted
Variable OR (95%CI) OR (95%CI)
Diabetes mellitus
No 1.00 1.00
Yes 1.03 (0.76-1.40) 0.99 (0.71-1.37)
Alcoholism
No 1.00 1.00
Yes 14.6 (8.25-25.7) 14.1 (7.87-25.4)
Periodontal disease
No 1.00 1.00
Yes 0.24 (0.06-1.00) 0.20 (0.04-0.88)
Esophageal ulcer
No 1.00 1.00
Yes 12.1 (7.01-21.0) 10.1 (5.70-17.9)
Esophageal reflux
No 1.00 1.00
Yes 4.70 (3.02-7.33) 3.47 (2.14-5.62)
COX-2 inhibitors
Never use 1.00 1.00
Ever use 1.40 (1.14-1.73) 1.06 (0.83-1.34)
Other NSAIDs
Never use 1.00 1.00
Ever use 3.28 (2.19-4.92) 2.73 (1.80-4.13)
Adjusted for sex, age, DM, alcoholism, periodontal disease, esophagus ulcer,
esophagus reflux, other NSAIDs and COX-2 inhibitors.
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Data analysis showed that patients taking anti-diabetic
drugs were at higher risk of esophageal cancer (Table 4).
The associations were significant for insulin (OR 2.58,
95%1.08-6.15) and sulfonylureas (OR 3.80, 95% 1.16-
12.5), and moderately significant for metformin.
Discussion
Studies investigating the relationship between malig-
nancy and DM have revealed conflicting results on the
association between DM and esophagus cancer, and
other cancers [8,23-39]. Based on histology, the distribu-
tion of squamous cell carcinoma and adenocarcinoma
varies among different geographic areas. Most of studies
on esophageal cancer have been conducted onadenocarcinoma of the esophagus for the populations in
Western countries [8,23-42]. The positive association be-
tween the risk of esophagesl cancer and DM in the
meta-analysis conducted by Huang et al consisted of
15 studies from Western countries and two studies
from Asian countries [8]. More than 80% of esophagus
cancer cases in the Asian are squamous cell carcinoma
[18]. Whether the risk of squamous cell carcinoma
of esophagus has a relationship with DM has not been
well explored. Our study makes up for the gap because
the previous study found that the squamous cell car-
cinoma is the major type of esophageal cancer in
Taiwan, accounting as high as 95% of patients with the
disease [18].
The present population-based case-control study failed
to find a significant association between DM and
esophagus cancer in Taiwan. Regardless no association
was found between DM and esophageal cancer, this
study shows several co-morbidities were much more
prevalent in cases than in controls. Consistent with
other studies [26,27,37-39], we also found heavy alcohol
Table 3 Adjusted odds ratios for esophageal cancer in relation to duration of diabetes mellitus
Duration of
diabetes (years)
Case Control Odds ratio (95% CI)
Number (%) Model 1 Model 2
0-2 6 44 1.00 1.00
≥2 51 178 2.10 (0.85-5.31) 2.28 (0.85-6.08)
Model 1 was adjusted for age and sex.
Model 2 was additionally adjusted for sex, age, alcoholism, periodontal disease, esophagus ulcer, esophagus reflux, other NSAIDs and COX-2 inhibitors.
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esophageal cancer. A Korean study found a relative risk
of 5.62 for mortality from esophageal cancer [26].
Japanese have an OR of 15 for esophageal caner among
high alcohol consumers [27]. The risk may increase fur-
ther to approximately 70-fold higher for those with alco-
hol flushing response, indicating individuals with
difficulty to metabolite alcohol are at a much higher risk
for the cancer. The exact mechanism of how alcoholic
beverage is associated with esophagus cancer risk is not
clear. Although ethanol has not been shown as car-
cinogenic in laboratory animals, it may act through
its major metabolite, acetaldehyde, a carcinogen in
animal models [27,38,43-45]. The dose-response relation-
ship with alcohol strongly indicates it as an independent
risk factor, particularly for esophagus squamous–cell
cancer [26,37,39].
Esophageal cancer is significantly associated with
esophageal ulcer and esophageal reflux, and medications
in this study. Both esophageal ulcer and esophageal re-
flux are likely the earlier signals for the subsequent de-
velopment of the cancer of esophagus due to esophageal
stricture formation, such as acid peptic and medication-Table 4 Odds ratios of esophageal cancer in relation to use o
Use of anti-diabetic drugs Case Co
Number (%)
Insulins
never use 7(12.3) 69
ever use 50(87.7) 15
Metformin
never use 5(8.77) 43
ever use 52(91.2) 17
Sulfonylureas
never use 4(7.02) 38
ever use 53(92.9) 18
Thiazolidinediones
never use 49(86.0) 18
ever use 8(14.0) 42
Alpha-glucosidase inhibitors
never use 48(84.2) 18
ever use 9(15.8) 34
Model 1 was adjusted for age and sex.
Model 2 was additionally adjusted for sex, age, alcoholism, periodontal disease, esoinduced. Peptic strictures account for most of esopha-
geal strictures [46-49]. Purdy et al. found esophageal
mucosa injury is associated with sloughing esopha-
gitis, chronic debilitation and medications [46]. García
Rodríguez et al. have also reported that long term
pharmacological gastric acid suppression is associated
with the risk of oesophageal and gastric adenocarcinoma
[47]. In this study, anti-diabetes drugs and other
NSAIDs are significantly associated with the disease.
Limitations
This study was conducted using insurance claims data, a
few limitations should be considered. First, smoking is
an important factor associated with esophageal cancer.
But, this information is not available in the insurance
claims. However, we are able to identify patients with
the diagnosis of alcoholism. There is strong relationship
between drinking and smoking. And we did find alcohol-
ism is an indicator that may well predict the cancer. Sec-
ond, this case-control study enrolled study subjects with
and without esophageal cancer identified from 2000 to
2009. The frequency matched study design fails to ob-
serve age difference between cases and controls.f anti-diabetic drugs
ntrol Odds ratio (95% CI)











phagus ulcer, esophagus reflux, other NSAIDs and COX-2 inhibitors.
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by randomly sampling controls, which revealed a mean
age of 15.4 years younger in the controls. This analysis
also showed that DM is not a factor associated with
esophageal cancer. Therefore, the frequency matched
samples are representative of the insured population. Fi-
nally, the insurance registry does not provide the infor-
mation on histological type and genotype of the cancer.
We were unable to differentiate whether the associated
risk factors different between squamous cell carcinoma
and adenocarcinoma among study subjects. It is likely
that the small portion of adenocarcinoma may not
change the association between DM and the risk of
esophageal cancer in the present study.Conclusions
In conclusion, the results of our study fail to show a sig-
nificant association between DM and the risk of esopha-
gus cancer. Instead, alcoholism, esophageal ulcer and
esophageal reflux are significant predictors for the can-
cer. Patients of heavy drink, with esophageal ulcer,
esophageal reflux and peptic strictures are at high risk of
developing the disease.
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